Credit Suisse’s Immuneering IMRX Stock Holding History

Credit Suisse’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-58	Closed	-$281	–	3495
2022 Q4	$281	Buy	+58	New	+$514	﹤0.01%	3595
2022 Q3	–	Sell	-10	Closed	–	–	4146
2022 Q2	$0	Buy	+10	New	+$53	﹤0.01%	4107

Other funds holding IMRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Credit Suisse's IMRX Position: Q1 2023 in Review

Credit Suisse sold out of Immuneering (IMRX) in Q1 2023, closing a stake of 58 shares — an estimated $281 sold.

Credit Suisse first reported a position in IMRX in Q2 2022 and held it in 2 quarters. The position peaked at $281 in Q4 2022. 34 funds tracked by Wall St. Rank hold IMRX as of Q1 2023.

Credit Suisse reported no remaining Immuneering position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 58 Immuneering shares in Q1 2023, an estimated $281.
Credit Suisse first reported a position in Immuneering in Q2 2022 and held it in 2 quarters.
Credit Suisse's Immuneering position peaked at $281 in Q4 2022.
34 funds tracked by Wall St. Rank held Immuneering as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.